MedPath

Drug eluting balloon venoplasty in arterio-­venous fistula stenosis

Phase 3
Completed
Conditions
Renal failure
Urological and Genital Diseases
Registration Number
ISRCTN14567609
Lead Sponsor
niversity Hospital Birmingham NHS Foundation Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
92
Inclusion Criteria

1. Arteriovenous (AV) fistulas with stenosis requiring percutaneous angioplasty identified on routine diagnostic imaging or causing clinical concern on dialysis
2. Fistula has been in use for at least 1 month and is more than 6 weeks old
3. Brachiocephalic AV fistula
4. Brachiobasilic AV fistula
5. Radiocephalic AV fistula (both proximal and distal)
6. Aged 18 years or over
7. Index lesion is less then the length of the DEB, and the reference vessel diameter is appropriate for treatment with the size range of DEB (4mm ­ 8mm diameter)
8. Capacity to give valid informed consent

Exclusion Criteria

1. Allergy to iodinated Intravenous contrast
2. Allergy to Paclitaxel
3. Prosthetic grafts
4. Long or tandem lesions that cannot be treated with a single DEB
5. Thrombosed Arterio­Venous fistulas
6. Women who are breastfeeding, pregnant or intending to become pregnant
7. Participants of child­bearing age who are unwilling to use a reliable form of contraception for the duration of the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Presence of at least 50% restenosis of index lesion requiring re-intervention is measured at 3, 6 and 12 months.
Secondary Outcome Measures
NameTimeMethod
<br> 1. Fistula failure rate (thrombosis or non-salvageable) is measured at 3, 6 and 12 months<br> 2. Re-intervention rate due to clinical or paraclinical indictions (without 50% restenosis) is measured at 3, 6 and 12 months<br>
© Copyright 2025. All Rights Reserved by MedPath